Itau Unibanco Holding S.A. Sells 189 Shares of Edwards Lifesciences Co. (NYSE:EW)

Itau Unibanco Holding S.A. lessened its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 24.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 588 shares of the medical research company’s stock after selling 189 shares during the quarter. Itau Unibanco Holding S.A.’s holdings in Edwards Lifesciences were worth $44,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at $26,000. Millstone Evans Group LLC bought a new position in Edwards Lifesciences during the fourth quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences during the fourth quarter valued at about $30,000. Roble Belko & Company Inc bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $46,000. Finally, Catalyst Capital Advisors LLC acquired a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $54,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 6,500 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total value of $492,375.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,555,402. The trade was a 12.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the transaction, the chief financial officer now directly owns 30,561 shares in the company, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 71,853 shares of company stock valued at $5,163,062 in the last ninety days. Insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Barclays boosted their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Robert W. Baird raised their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a “neutral” rating in a research note on Thursday, April 24th. Morgan Stanley boosted their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. Piper Sandler raised Edwards Lifesciences from a “neutral” rating to an “overweight” rating and raised their price target for the company from $73.00 to $80.00 in a research report on Thursday, April 24th. Finally, Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a “hold” rating in a research report on Friday, April 25th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus target price of $79.45.

Edwards Lifesciences Trading Up 0.5 %

Shares of EW opened at $75.57 on Friday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market cap of $44.42 billion, a PE ratio of 10.84, a PEG ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The stock has a 50 day simple moving average of $71.17 and a 200-day simple moving average of $71.31.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period in the prior year, the company posted $0.66 earnings per share. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.